Search

Your search keyword '"Acquavella, Nicolas"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Acquavella, Nicolas" Remove constraint Author: "Acquavella, Nicolas"
32 results on '"Acquavella, Nicolas"'

Search Results

1. Future perspectives in melanoma research. Meeting report from the ¿Melanoma Bridge. Napoli, December 2nd-4th 2012¿

3. Data from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

9. Supplementary Materials and Methods from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

10. Supplementary Figures 1 - 12 and Tables 1 - 11 from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

11. Supplemental Figure S4 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

12. Data from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

13. Supplemental Figure Legend from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

15. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma

18. 391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors

21. Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

22. Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

23. Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

24. A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer

29. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

30. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31. Future perspectives in melanoma research. Meeting report from the 'Melanoma Bridge. Napoli, December 2nd-4th 2012'

Catalog

Books, media, physical & digital resources